Medication-assisted Treatment Market Size, Share, and Growth Forecast 2026 - 2033

The global medication-assisted treatment market size is likely to be valued at US$6.6 billion in 2026 and is estimated to reach US$11.5 billion by 2033, growing at a CAGR of 8.3% during the forecast period from 2026 to 2033, driven by the rising burden of opioid and alcohol use disorders, high adoption of long-acting injectable treatments, wide access to evidence-based addiction care, and increasing government support for medication-based treatment programs.

Driver - Rising Opioid Use Worldwide to Push Demand for Treatment

The continuing burden of opioid use is creating a rising demand for Medication-Assisted Treatment (MAT), particularly in countries affected by fentanyl, heroin, and prescription opioid misuse. The World Health Organization (WHO) estimates that around 61 million people engaged in non-medical opioid use in 2023, while opioids were responsible for about 450,000 of the roughly 600,000 drug-related deaths worldwide.

Fewer than 10% of people living with drug use disorders receive treatment. This large treatment gap creates substantial room for MAT providers to expand access. The need is mainly strong for OUD, where untreated dependence can quickly lead to relapse and fatal overdose. WHO continues to recommend opioid agonist treatment with methadone and buprenorphine because of its established effect on treatment retention, non-medical opioid use, and mortality.

Strong Clinical Evidence to Boost Adoption of Medication-based Care

Clinical evidence is shifting treatment away from detoxification alone and toward sustained medication-based care. The Centers for Disease Control and Prevention (CDC) states that medication treatment for OUD is associated with lower overdose and mortality risk, while also reducing cravings, illicit opioid use, and withdrawal symptoms. The agency recommends that clinicians offer or arrange evidence-based medication treatment for people with OUD.

The WHO likewise continues to identify opioid agonist maintenance treatment as the approach with the strongest evidence across several important outcomes. This surging clinical consensus supports wider prescribing and greater integration of MAT into mainstream healthcare. The evidence is further creating opportunities beyond specialist addiction clinics. Buprenorphine can be prescribed in a range of clinical settings, making it easier to incorporate OUD treatment into primary care and other community-based services.

Restraint - Dependence May Make Treatment Discontinuation Difficult

Physical dependence is projected to limit the pace at which some patients discontinue medication-assisted treatment. Buprenorphine and methadone are opioid medicines, so long-term use can produce physical dependence even when the treatment is medically appropriate. SAMHSA notes that withdrawal can occur when patients reduce or stop these medicines, and recommends medically supervised, individualized tapering rather than abrupt discontinuation.

The agency further warns that stopping MOUD too quickly can increase the risk of OUD recurrence and overdose. This can make some patients reluctant to start treatment when they expect long-term medication use. Also, physical dependence should not be confused with addiction, as properly managed MOUD reduces illicit opioid use and overdose risk.

Opportunity- Long-acting Formulations to Reduce the Burden of Daily Dosing

Long-acting injectable formulations represent one of the clearest opportunities in medication-assisted treatment. Daily oral therapy can be difficult for patients who face unstable housing, transportation problems, stigma, or inconsistent access to healthcare. Extended-release buprenorphine can reduce the number of dosing decisions and help maintain therapeutic drug levels over longer periods. CDC recognizes extended-release buprenorphine as one of the available treatment formats for OUD.

The opportunity is becoming more significant as clinical guidance catches up with product innovation. In April 2026, WHO extended its recommendation to include new long-acting injectable buprenorphine formulations, while retaining strong recommendations for oral buprenorphine and methadone. This provides an important regulatory and clinical signal for manufacturers developing injectable products.

Expanding Primary Care to Unlock Untapped Patients

MAT providers have a major opportunity to move treatment beyond specialized addiction centers. The removal of the U.S. DATA waiver requirement has made buprenorphine prescribing easier for eligible practitioners and has opened the door for more primary-care practices to offer treatment. SAMHSA specifically identifies integration into primary and other care settings as a way to increase access to lifesaving treatment.

This model can be especially valuable for patients who already visit doctors for chronic diseases, pregnancy care, mental-health services, or other routine needs. Combining addiction treatment with these services can reduce stigma and eliminate additional clinic visits. For pharmaceutical companies, wide prescribing also creates opportunities to build partnerships with primary-care networks, health systems, pharmacies, and telehealth providers.

Drug Type Insights

Buprenorphine is predicted to lead with a share of about 40.5% in 2026, as it combines superior control of opioid withdrawal and cravings with a comparatively favorable safety profile. As a partial opioid agonist, it produces a ceiling effect on respiratory depression, which lowers the risk associated with full opioid agonists when used as directed. Its flexible delivery options also strengthen adoption. Patients can receive sublingual tablets or films for regular treatment, while extended-release injections can reduce the need for daily dosing.

Naltrexone is estimated to be the fastest-growing segment in the forecast period, as it provides a non-opioid approach to addiction treatment. Unlike buprenorphine and methadone, it is an opioid antagonist and does not produce opioid effects or physical opioid dependence. This makes it attractive for patients who have completed opioid withdrawal and prefer an abstinence-based treatment option. Its use in both OUD and AUD also gives it a broader application base than medicines restricted mainly to OUD. Extended-release injectable naltrexone is another advantage because it can reduce the adherence challenges associated with daily oral medication.

Application Insights

Opioid Use Disorder (OUD) is anticipated to dominate with a share of around 82.4% in 2026, as opioid dependence carries a particularly high risk of overdose and death, creating an urgent need for medicines that can control cravings, prevent withdrawal, and reduce illicit opioid use. The WHO estimates that opioids were responsible for about 450,000 of roughly 600,000 drug-related deaths globally in 2023. The continuing spread of potent synthetic opioids, especially fentanyl in North America, has further increased the need for continuous treatment.

Alcohol Use Disorder (AUD) is expected to remain in the second position in 2026, as a large treatment gap exists between the number of people affected by alcohol dependence and those receiving pharmacological treatment. In the U.S., SAMHSA reported that 25.7 million people aged 12 or older had AUD in 2025, while only 2.6% received medication for the condition. Naltrexone already provides an established pharmacological option, creating a base for further adoption. At the same time, researchers are investigating new mechanisms for reducing alcohol craving and consumption.

North America Medication-assisted Treatment Market Trends

North America is predicted to dominate in 2026 globally with a share of approximately 44.1%, as the U.S. has the most developed medication-based response to OUD, supported by FDA-approved medicines, extensive treatment infrastructure, insurance coverage, telehealth access, and major investment in addiction-treatment innovation. In 2025, about 2.1 million Americans aged 12 or older received MOUD, while more than 600,000 people with OUD received MOUD among those with a past-year disorder. The region also has an established commercial network around long-acting buprenorphine. Indivior reported that more than 545,000 U.S. patients had been prescribed SUBLOCADE since launch by June 2026.

U.S. Medication-assisted Treatment Market Trends

A share of nearly 62.3% is expected to be held by the U.S. in 2026 in North America, as fentanyl has increased the need for effective, sustained OUD treatment, while regulatory changes have removed important access barriers to buprenorphine. SAMHSA notes that the federal buprenorphine waiver requirement was removed, allowing eligible practitioners to prescribe buprenorphine without the former DATA-waiver process. The market is also benefiting from rapid uptake of long-acting injections.

Asia Pacific Medication-assisted Treatment Market Trends

Asia Pacific is anticipated to be the fastest-growing region globally in 2026 with a share of around 23.8%, as various countries are still expanding formal treatment capacity, integrating opioid-dependence care into public-health programs, and improving access to evidence-based medicines. The WHO has specifically highlighted the need to expand affordable opioid-dependence treatment globally, while its 2025 guidance emphasized maintaining opioid agonist treatment as an essential health service.

China Medication-assisted Treatment Market Trends

China will likely lead in Asia Pacific in 2026 with a share of about 37.8%, as its healthcare sector continues to use structured medication-based approaches for opioid dependence, while public-health authorities emphasize comprehensive treatment that combines medication, psychological care, and social rehabilitation. National guidance recognizes maintenance treatment for opioid dependence as part of the country's treatment framework. The opportunity remains substantial because treatment models are still more restricted than in mature Western markets, leaving scope for wide use of modern formulations and expanded community-based care.

India Medication-assisted Treatment Market Trends

In 2026, India is projected to account for a share of just about 21.5% in Asia Pacific, as government programs are expanding addiction prevention, treatment, rehabilitation, and harm-reduction services across the country. In March 2026, the Ministry of Health and Family Welfare reported that 349 rehabilitation centers were operational nationwide, alongside other treatment and demand-reduction initiatives. India also has established experience with opioid substitution therapy, including buprenorphine-based approaches, through national HIV and harm-reduction programs.

Europe Medication-assisted Treatment Market Trends

Europe will likely witness steady growth over the forecast period with a global share of roughly 14.9% in 2026, as opioid-substitution treatment is well established across several countries, while governments are now supporting long-acting formulations. The WHO continues to recommend opioid agonist maintenance treatment, and several European healthcare systems are expanding access to injectable buprenorphine. The U.K., Germany, France, the Nordic countries, and Spain are important contributors, with treatment systems focused on improving retention and reducing the burden of daily dosing.

Germany Medication-assisted Treatment Market Trends

Germany is predicted to register a substantial share of approximately 32.2% in 2026 in Europe, as opioid-agonist treatment is already embedded in the healthcare system, while demand is increasing for flexible treatment formats. Germany had about 80,400 patients receiving opioid-agonist therapy as of July 2024, with the number of patients rising by around 4% over the previous decade. Long-acting buprenorphine is also gaining ground. Camurus reported strong Buvidal performance in Germany in 2026, alongside growth in other European markets.

U.K. Medication-assisted Treatment Market Trends

A regional share of nearly 26.3% is predicted to be held by the U.K. in 2026, as government guidance is increasingly focused on improving opioid-substitution treatment and expanding access to newer buprenorphine formulations. England recorded 329,646 adults in contact with drug and alcohol treatment services during 2024–2025, a 6% increase from the previous year, with opiate-related treatment remaining the largest substance category. The U.K. is also preparing for wider use of long-acting buprenorphine, while NHS funding changes are supporting renewed growth of injectable treatment.

The global medication-assisted treatment market is moderately consolidated, with a mix of specialized addiction-treatment companies, large pharmaceutical manufacturers, generic-drug suppliers, and developers of long-acting formulations. The market is led by companies with established buprenorphine, methadone, and naltrexone portfolios, while competition is mainly shifting toward long-acting injectable products.

Indivior has a dominant position in long-acting buprenorphine through SUBLOCADE, while Camurus and Braeburn are expanding the use of weekly and monthly buprenorphine. Generic manufacturers also keep competition high in oral buprenorphine, buprenorphine/naloxone, methadone, and naltrexone. The WHO's 2026 guidance further supports the wide use of oral and long-acting buprenorphine, which is encouraging pharmaceutical companies to expand access to these formulations.

Key Industry Developments:

• In August 2026, Indivior and Supernus Pharmaceuticals announced a definitive all-stock merger of equals. The companies said the combination would create a larger CNS-focused pharmaceutical business, with Indivior contributing its addiction-treatment portfolio, including SUBLOCADE. The transaction is expected to close in the fourth quarter of 2026, subject to approvals.
• In March 2026, an NIH-funded randomized clinical trial evaluating weekly BRIXADI in pregnant women with OUD was published in JAMA Internal Medicine. The study expanded the evidence base for long-acting buprenorphine during pregnancy and postpartum, an area where treatment adherence and continuity of care are major clinical concerns.
• In March 2026, Indivior reported real-world evidence showing that patients adherent to monthly SUBLOCADE had 42% lower adjusted non-MOUD medical costs than patients adherent to other forms of MOUD. The study also found lower inpatient, emergency-department, and detoxification utilization among adherent SUBLOCADE patients, strengthening the economic case for long-acting treatment.